This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.20% per year. These returns cover a period from January 1, 1988 through April 1, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Zacks News
Should You Buy Insmed (INSM) Ahead of Earnings?
by Zacks Equity Research
Insmed (INSM) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Will Tango Therapeutics, Inc. (TNGX) Report Negative Q1 Earnings? What You Should Know
by Zacks Equity Research
Tango Therapeutics (TNGX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -13.27% and 0.15%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Reports Q3 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -3.77% and 0.27%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?
Amgen (AMGN) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Amgen (AMGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Up on Positive Data From MAC Lung Disease Study
by Zacks Equity Research
Insmed's (INSM) shares rise on positive data from the late-stage ARISE study evaluating Arikayce for newly infected lung disease caused by MAC.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -61.82% and 9.94%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
G1 Therapeutics (GTHX) Tops Q2 Earnings and Revenue Estimates
by Zacks Equity Research
G1 Therapeutics (GTHX) delivered earnings and revenue surprises of 182.35% and 49.58%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?
Insmed (INSM) Reports Q1 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -8.33% and 1.29%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
Revance Therapeutics, Inc. (RVNC) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
by Zacks Equity Research
Revance Therapeutics, Inc. (RVNC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Reports Q4 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -20% and 9.85%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Y-mAbs Therapeutics, Inc. (YMAB) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
Y-mAbs Therapeutics, Inc. (YMAB) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Insmed (INSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Wall Street Analysts Believe Insmed (INSM) Could Rally 98.26%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Insmed (INSM) points to a 98.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Insmed (INSM) Reports Q3 Loss, Misses Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of -22.47% and 0.42%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
Voyager Therapeutics (VYGR) Expected to Beat Earnings Estimates: Should You Buy?
by Zacks Equity Research
Voyager Therapeutics (VYGR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Insmed (INSM) Report Negative Earnings Next Week? What You Should Know
by Zacks Equity Research
Insmed (INSM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Insmed (INSM) Upgraded to Buy: What Does It Mean for the Stock?
by Zacks Equity Research
Insmed (INSM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Bluebird (BLUE) Surges 15.7%: Is This an Indication of Further Gains?
by Zacks Equity Research
Bluebird (BLUE) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Insmed (INSM) Reports Q2 Loss, Tops Revenue Estimates
by Zacks Equity Research
Insmed (INSM) delivered earnings and revenue surprises of 10.11% and 11.81%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Castle Biosciences, Inc. (CSTL) Q2 Earnings Expected to Decline
by Zacks Equity Research
Castle Biosciences, Inc. (CSTL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.